OTLKW

Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW

Delisted

OTLKW was delisted on the 16th of February, 2022.

Back to rankings
 

About: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Employees: 9

Healthcare Drug Manufacturers - General
Charts implemented using Lightweight Charts™